Skip to main content

Acorda Therapeutics, Inc.

ACORDelisted Apr 25, 2024
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001008848

Acorda Therapeutics, Inc. was delisted on Apr 25, 2024; its insiders filed their last Form 4 on Jun 23, 2023; 17 institutions reported holding it in 13F filings for Q1 2024, worth $2.13M in total; no superinvestor held it.

Q3 2021 vs. Q2 2021

How the institutions holding Acorda Therapeutics, Inc. changed between Q2 2021 and Q3 2021.

All holders in Q3 2021All holders in Q2 2021

13F holders of ACOR: Q2 2021 compared with Q3 2021
MeasureQ2 2021Q3 2021Change
Holders3736−1
Shares3.79M3.20M−582.8K (−15.4%)
Value$18.1M$14.7M−$3.33M (−18.4%)

New holders (5)

Institutions that held Acorda Therapeutics, Inc. at the end of Q3 2021 but not at the end of Q2 2021.

Institutions new to ACOR in Q3 2021
InstitutionSharesValue% of portfolio
AE Wealth Management LLC40,457$186.0K0.00%
Susquehanna Fundamental Investments, LLC23,800$109.0K0.00%
Apollon Wealth Management, LLC15,000$69.0K0.01%
Two Sigma Advisers, LP12,000$55.0K0.00%
Two Sigma Investments, LP10,855$50.0K0.00%

Sold out (6)

Institutions that held Acorda Therapeutics, Inc. at the end of Q2 2021 and filed for Q3 2021 without it.

Institutions that sold out of ACOR in Q3 2021
InstitutionShares, Q2 2021Value, Q2 2021
Jacobs Levy Equity Management, Inc135,190$645.0K
Squarepoint Ops LLC49,269$235.0K
Citadel Advisors LLC44,666$213.0K
HN Saltoro Capital, LP11,853$57.0K
Virtu Financial LLC10,119$48.0K
Citigroup Inc67$0